A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma

Tarek Assi; Joseph Kattan; Elie El Rassy; Charles Honore; Sarah Dumont; Olivier Mir; Axel Le Cesne

doi:10.1016/j.ctrv.2018.11.003

A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma

Tarek Assi, Joseph Kattan, Elie El Rassy, Charles Honore, Sarah Dumont, Olivier Mir, Axel Le Cesne

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

27 Citations (Scopus)

Résumé

Myxoid liposarcoma (MLS) is a rare mesenchymal tumor that constitutes 10–20% of all liposarcomas. MLS is a translocation-related sarcoma (TRS) related to the chromosomal translocation t(12:16) (q13:p11), producing the FUS-CHOP oncoprotein that constitutes one of the main targets of trabectedin in MLS patients. It is known to be chemosensitive namely to trabectedin in contrast to other soft tissue sarcomas. The efficacy of this agent in MLS have been demonstrated in different settings including treatment-naïve and pre-treated patients with both locally advanced and metastatic disease. However, the benefits of trabectedin in MLS are shadowed by the limited activity of this drug in other subtypes of sarcomas that are enrolled within the same trials. This prompted us to screen the medical literature for clinical data that evaluates the efficacy and safety of trabectedin in MLS. In this review, we will summarize the available evidence for the applicability of trabectedin in MLS.

langue originale	Anglais
Pages (de - à)	37-44
Nombre de pages	8
journal	Cancer Treatment Reviews
Volume	72
Les DOIs	https://doi.org/10.1016/j.ctrv.2018.11.003
état	Publié - 1 janv. 2019

Accès au document

10.1016/j.ctrv.2018.11.003

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{7fed4da447a74e04b53def55743a72f3,

title = "A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma",

abstract = "Myxoid liposarcoma (MLS) is a rare mesenchymal tumor that constitutes 10–20% of all liposarcomas. MLS is a translocation-related sarcoma (TRS) related to the chromosomal translocation t(12:16) (q13:p11), producing the FUS-CHOP oncoprotein that constitutes one of the main targets of trabectedin in MLS patients. It is known to be chemosensitive namely to trabectedin in contrast to other soft tissue sarcomas. The efficacy of this agent in MLS have been demonstrated in different settings including treatment-na{\"i}ve and pre-treated patients with both locally advanced and metastatic disease. However, the benefits of trabectedin in MLS are shadowed by the limited activity of this drug in other subtypes of sarcomas that are enrolled within the same trials. This prompted us to screen the medical literature for clinical data that evaluates the efficacy and safety of trabectedin in MLS. In this review, we will summarize the available evidence for the applicability of trabectedin in MLS.",

keywords = "MLS, Myxoid liposarcomas, Trabectedin",

author = "Tarek Assi and Joseph Kattan and {El Rassy}, Elie and Charles Honore and Sarah Dumont and Olivier Mir and {Le Cesne}, Axel",

note = "Publisher Copyright: {\textcopyright} 2018",

year = "2019",

month = jan,

day = "1",

doi = "10.1016/j.ctrv.2018.11.003",

language = "English",

volume = "72",

pages = "37--44",

journal = "Cancer Treatment Reviews",

issn = "0305-7372",

}

TY - JOUR

T1 - A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma

AU - Assi, Tarek

AU - Kattan, Joseph

AU - El Rassy, Elie

AU - Honore, Charles

AU - Dumont, Sarah

AU - Mir, Olivier

AU - Le Cesne, Axel

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Myxoid liposarcoma (MLS) is a rare mesenchymal tumor that constitutes 10–20% of all liposarcomas. MLS is a translocation-related sarcoma (TRS) related to the chromosomal translocation t(12:16) (q13:p11), producing the FUS-CHOP oncoprotein that constitutes one of the main targets of trabectedin in MLS patients. It is known to be chemosensitive namely to trabectedin in contrast to other soft tissue sarcomas. The efficacy of this agent in MLS have been demonstrated in different settings including treatment-naïve and pre-treated patients with both locally advanced and metastatic disease. However, the benefits of trabectedin in MLS are shadowed by the limited activity of this drug in other subtypes of sarcomas that are enrolled within the same trials. This prompted us to screen the medical literature for clinical data that evaluates the efficacy and safety of trabectedin in MLS. In this review, we will summarize the available evidence for the applicability of trabectedin in MLS.

AB - Myxoid liposarcoma (MLS) is a rare mesenchymal tumor that constitutes 10–20% of all liposarcomas. MLS is a translocation-related sarcoma (TRS) related to the chromosomal translocation t(12:16) (q13:p11), producing the FUS-CHOP oncoprotein that constitutes one of the main targets of trabectedin in MLS patients. It is known to be chemosensitive namely to trabectedin in contrast to other soft tissue sarcomas. The efficacy of this agent in MLS have been demonstrated in different settings including treatment-naïve and pre-treated patients with both locally advanced and metastatic disease. However, the benefits of trabectedin in MLS are shadowed by the limited activity of this drug in other subtypes of sarcomas that are enrolled within the same trials. This prompted us to screen the medical literature for clinical data that evaluates the efficacy and safety of trabectedin in MLS. In this review, we will summarize the available evidence for the applicability of trabectedin in MLS.

KW - MLS

KW - Myxoid liposarcomas

KW - Trabectedin

UR - http://www.scopus.com/inward/record.url?scp=85056769947&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2018.11.003

DO - 10.1016/j.ctrv.2018.11.003

M3 - Review article

C2 - 30468937

AN - SCOPUS:85056769947

SN - 0305-7372

VL - 72

SP - 37

EP - 44

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

ER -